• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.肝细胞癌全身治疗反应的放射学标准。
Hepat Oncol. 2017 Oct;4(4):129-137. doi: 10.2217/hep-2017-0018. Epub 2017 Nov 17.
2
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.索拉非尼治疗晚期肝细胞癌患者的CT成像结果：替代反应标准（Choi标准、欧洲肝脏研究协会标准以及改良实体瘤疗效评价标准（mRECIST））与RECIST 1.1标准的对比
Eur J Radiol. 2016 Jan;85(1):103-112. doi: 10.1016/j.ejrad.2015.10.024. Epub 2015 Nov 5.
3
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.EASL 和 mRECIST 评价索拉非尼联合经动脉化疗栓塞治疗肝细胞癌的疗效反应可预测患者的生存。
Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.
4
Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.从世界卫生组织（WHO）到欧洲肝脏研究学会（EASL）及改良 RECIST（mRECIST）在肝细胞癌中的演变：肿瘤反应评估的考量因素
Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):335-48. doi: 10.1586/17474124.2015.959929. Epub 2014 Nov 5.
5
Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.使用增强标准评估肝细胞癌患者对索拉非尼的初始反应。
Hepatol Int. 2013 Jun;7(2):703-13. doi: 10.1007/s12072-013-9425-4. Epub 2013 Feb 12.
6
Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?在多期CT中应用哪些标准可以预测接受传统经动脉化疗栓塞术（TACE）治疗的肝细胞癌患者的早期肿瘤反应：RECIST、mRECIST、EASL还是qEASL？
Cardiovasc Intervent Radiol. 2018 Mar;41(3):433-442. doi: 10.1007/s00270-017-1829-4. Epub 2017 Oct 30.
7
Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.实体瘤改良反应评估标准和欧洲肝脏研究协会标准在早期时间点使用延迟期成像可预测钇-90放射性栓塞术后不可切除肝内胆管癌患者的生存情况。
J Vasc Interv Radiol. 2014 Feb;25(2):256-65. doi: 10.1016/j.jvir.2013.10.056.
8
EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.EASL 和 mRECIST 应答是接受冷冻消融治疗的肝细胞癌患者生存的独立预测因素。
Eur J Gastroenterol Hepatol. 2013 May;25(5):620-7. doi: 10.1097/MEG.0b013e32835ced13.
9
Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.肝移植前经化疗栓塞治疗的肝细胞癌患者，计算机断层扫描显示的肿瘤反应与病理坏死的相关性
Liver Transpl. 2016 Nov;22(11):1491-1500. doi: 10.1002/lt.24615.
10
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.索拉非尼治疗肝细胞癌肿瘤反应评估中操作者间变异性和误差源。
Eur Radiol. 2018 Sep;28(9):3611-3620. doi: 10.1007/s00330-018-5393-3. Epub 2018 Apr 9.

引用本文的文献

1
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.免疫治疗时代肝细胞癌放射学反应评估的演变情况：替代终点的优势与不足
Biomedicines. 2022 Nov 6;10(11):2827. doi: 10.3390/biomedicines10112827.
2
Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.肝细胞癌放射治疗进展与创新的临床应用
J Clin Transl Res. 2021 Nov 6;7(6):811-833. eCollection 2021 Dec 28.
3
Experience with regorafenib in the treatment of hepatocellular carcinoma.瑞戈非尼治疗肝细胞癌的经验
Therap Adv Gastroenterol. 2021 May 28;14:17562848211016959. doi: 10.1177/17562848211016959. eCollection 2021.
4
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.瑞戈非尼联合其他全身治疗：探索肝细胞癌中有前景的治疗组合
J Hepatocell Carcinoma. 2021 May 26;8:477-492. doi: 10.2147/JHC.S251729. eCollection 2021.
5
A simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles.一种使用全氟丁烷微泡对比增强超声定量预测乐伐替尼对肝细胞癌疗效的简化方法。
Quant Imaging Med Surg. 2021 Jun;11(6):2766-2774. doi: 10.21037/qims-20-965.
6
Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.索拉非尼可降低 HCV 相关肝细胞癌的肿瘤生长速度和肝功能恶化速度。
J Hepatol. 2021 Oct;75(4):879-887. doi: 10.1016/j.jhep.2021.05.015. Epub 2021 May 27.
7
Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.基于不可治疗性经动脉化疗栓塞术（unTACEable）进展评估经动脉化疗栓塞术（TACE）联合索拉非尼治疗肝细胞癌的益处
Cancer Manag Res. 2021 May 18;13:4013-4029. doi: 10.2147/CMAR.S304591. eCollection 2021.
8
Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.经动脉化疗栓塞术后附加消融治疗与肝癌患者生存率的关系。
JAMA Netw Open. 2020 Nov 2;3(11):e2023942. doi: 10.1001/jamanetworkopen.2020.23942.
9
Changing TACTICS in intermediate HCC: TACE plus sorafenib.中晚期肝癌治疗策略的改变：经动脉化疗栓塞术（TACE）联合索拉非尼
Gut. 2020 Aug;69(8):1374-1376. doi: 10.1136/gutjnl-2020-320692. Epub 2020 Mar 13.
10
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.印度肝脏研究全国协会关于印度肝细胞癌预防、诊断和管理的共识2019年更新：普里II建议
J Clin Exp Hepatol. 2020 Jan-Feb;10(1):43-80. doi: 10.1016/j.jceh.2019.09.007. Epub 2019 Sep 23.

本文引用的文献

1
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.索拉非尼系统治疗肝细胞癌：regorafenib 试验后的问题与机遇。
Future Oncol. 2017 Sep;13(21):1893-1905. doi: 10.2217/fon-2017-0166. Epub 2017 Jul 11.
2
mRECIST for systemic therapies: More evidence is required before recommendations can be made.用于全身治疗的改良RECIST标准：在提出建议之前，还需要更多证据。
J Hepatol. 2017 Jul;67(1):195. doi: 10.1016/j.jhep.2017.02.033. Epub 2017 Mar 16.
3
Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.肝细胞癌治疗疗效评估：缓解率、疾病进展延迟还是两者皆非。
J Hepatol. 2017 Jun;66(6):1114-1117. doi: 10.1016/j.jhep.2017.02.032. Epub 2017 Mar 9.
4
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.mRECIST 预测晚期肝细胞癌的生存：比较尼达尼布与索拉非尼的两项随机 II 期试验分析。
Liver Int. 2017 Jul;37(7):1047-1055. doi: 10.1111/liv.13359. Epub 2017 Feb 2.
5
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
6
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.索拉非尼治疗晚期肝细胞癌患者的CT成像结果：替代反应标准（Choi标准、欧洲肝脏研究协会标准以及改良实体瘤疗效评价标准（mRECIST））与RECIST 1.1标准的对比
Eur J Radiol. 2016 Jan;85(1):103-112. doi: 10.1016/j.ejrad.2015.10.024. Epub 2015 Nov 5.
7
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.实体瘤改良疗效评价标准在评估晚期肝细胞癌患者对索拉非尼的疗效方面优于实体瘤疗效评价标准。
BMC Res Notes. 2015 Oct 26;8:609. doi: 10.1186/s13104-015-1565-2.
8
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.根据EASL标准和mRECIST标准评估局部区域治疗的肝细胞癌患者客观缓解的预后相关性：一项基于文献的荟萃分析
PLoS One. 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. eCollection 2015.
9
Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.使用增强标准评估肝细胞癌患者对索拉非尼的初始反应。
Hepatol Int. 2013 Jun;7(2):703-13. doi: 10.1007/s12072-013-9425-4. Epub 2013 Feb 12.
10
Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version).《肝癌疗效评价标准（RECICL）》（2015年修订版）
Hepatol Res. 2016 Jan;46(1):3-9. doi: 10.1111/hepr.12542. Epub 2015 Aug 4.

肝细胞癌全身治疗反应的放射学标准。

Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.

作者信息

Tovoli Francesco, Renzulli Matteo, Granito Alessandro, Golfieri Rita, Bolondi Luigi

机构信息

Department of Medical & Surgical Sciences, University of Bologna, Italy.

Radiology Unit, S.Orsola-Malpighi Bologna University Hospital, Italy.

出版信息

Hepat Oncol. 2017 Oct;4(4):129-137. doi: 10.2217/hep-2017-0018. Epub 2017 Nov 17.

DOI:10.2217/hep-2017-0018
PMID:30191059
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6096444/
Abstract

Sorafenib has been the only approved systemic therapy for hepatocellular carcinoma until very recently. However, the radiologic assessment of its biological activity is a disputed matter as at least five different criteria have been proposed. In this review, we describe the characteristic of the Response Evaluation Criteria In Solid Tumors (RECIST), European Association for the Study of The Liver (EASL), modified RECIST (mRECIST), Response Evaluation Criteria In the Cancer of the Liver (RECICL) and Choi criteria. The existing comparative studies are reported together with recent pieces of evidence, analyzing the reasons behind the split between recommendations of the scientific societies and regulatory agencies. Future perspectives in the wake of the impending results of the immunotherapy trials are also discussed.

摘要

直到最近，索拉非尼一直是唯一被批准用于肝细胞癌的全身治疗药物。然而，对其生物学活性的放射学评估是一个有争议的问题，因为至少已经提出了五种不同的标准。在本综述中，我们描述了实体瘤疗效评价标准（RECIST）、欧洲肝脏研究协会（EASL）、改良RECIST（mRECIST）、肝癌疗效评价标准（RECICL）和崔氏标准的特点。报告了现有的比较研究以及最新证据，分析了科学协会和监管机构建议之间存在分歧的原因。还讨论了免疫治疗试验即将取得的结果所带来的未来前景。